Hikma Pharmaceuticals Plc Given Consensus Rating of “Hold” by Analysts (LON:HIK)
Hikma Pharmaceuticals Plc (LON:HIK) has earned a consensus rating of “Hold” from the ten brokerages that are presently covering the company, Analyst Ratings News reports. Six equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is GBX 1,590 ($27.06).
Shares of Hikma Pharmaceuticals Plc (LON:HIK) traded down 1.91% on Tuesday, hitting GBX 1640.00. The stock had a trading volume of 108,178 shares. Hikma Pharmaceuticals Plc has a 52 week low of GBX 903.50 and a 52 week high of GBX 1733.00. The stock’s 50-day moving average is GBX 1649.68 and its 200-day moving average is GBX 1453.. The company’s market cap is £3.243 billion.
A number of analysts have recently weighed in on HIK shares. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, June 17th. They now have a GBX 1,400 ($23.83) price target on the stock. Separately, analysts at Barclays reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Monday, June 9th. They now have a GBX 1,890 ($32.16) price target on the stock. Finally, analysts at Barclays reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, May 21st. They now have a GBX 1,750 ($29.78) price target on the stock.
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.